Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Both Amazon and Rite Aid offered no comment for this story.
There were five fatalities out of seven patients with sepsis, all in the tozadenant group.
Bloomberg noted that Takeda’s CEO is looking at making Takeda a nimble company, but one with a deeply entrenched R&D focus.
The company’s demise was explained in a blog post by Atlas Venture partner Bruce Booth.
Shares of Merit Medical Systems have jumped more than 9 percent this morning after the company announced it plunked down $100M for two product lines belonging to Becton, Dickinson and Company.
The company sold the stake to Sapphire I Holdings at an undisclosed price.
Denali plans to make a $100M IPO under the symbol DNLI.
Investors love to speculate on M&A, and one of the hottest topics of speculation recently has been whether someone will buy BMS.
Creat Group will attempt to restructure its $1.5M offer to acquire Biotest after U.S. regulators nixed the deal.
The public listing is expected to value the business at around $46 billion.